Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Tazemetostat for the Treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 Patient

NCT05018975 is registered in ClinicalTrials.gov with Loma Linda University as lead sponsor.

NCT NCT05018975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05018975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Tazemetostat for the Treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 Patient
Lead sponsor
Loma Linda University
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2022
Completion date
September 21, 2023
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 acute respiratory distress syndrome, cytokine release syndrome